DDInter704 DDInter1281
Everolimus is a derivative of Rapamycin (sirolimus), and works similarly to Rapamycin as an mTOR (mammalian target of rapamycin) inhibitor. It is currently used as an immunosuppressant to prevent rejection of organ transplants. In a similar fashion to other mTOR inhibitors Everolimus' effect is solely on the mTORC1 protein and not on the mTORC2 protein.
Neratinib was approved in July 2017 for use as an extended adjuvant therapy in Human Epidermal Growth Factor Receptor 2 (HER2) positive breast cancer. Approval was granted to Puma Biotechnology Inc. for the tradename Nerlynx. Neratinib is currently under investigation for use in many other forms of cancer.
Everolimus {u} (Compound) resembles {v} (Compound) Sirolimus
Sirolimus {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Neratinib
Everolimus {u} (Compound) downregulates {v} (Gene) ERBB2
ERBB2 {u} (Gene) is bound by {v} (Compound) Lapatinib
Lapatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Neratinib
Everolimus {u} (Compound) resembles {v} (Compound) Sirolimus
Sirolimus {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lapatinib
Lapatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Neratinib
Everolimus {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Lapatinib
Lapatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Neratinib
Everolimus {u} (Compound) downregulates {v} (Gene) ERBB2
ERBB2 {u} (Gene) is downregulated by {v} (Compound) Digoxin
Digoxin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Neratinib
Everolimus {u} (Compound) resembles {v} (Compound) Sirolimus
Sirolimus {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Norethisterone
Norethisterone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Neratinib
Everolimus {u} (Compound) upregulates {v} (Gene) VAV3
VAV3 {u} (Gene) is upregulated by {v} (Compound) Lapatinib
Lapatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Neratinib
Everolimus {u} (Compound) resembles {v} (Compound) Sirolimus
Sirolimus {u} may lead to a major life threatening interaction when taken with {v} Teriflunomide
Teriflunomide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Neratinib
Everolimus {u} (Compound) downregulates {v} (Gene) CCNB2
CCNB2 {u} (Gene) is upregulated by {v} (Compound) Lapatinib
Lapatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Neratinib
Everolimus {u} (Compound) upregulates {v} (Gene) BAMBI
BAMBI {u} (Gene) is downregulated by {v} (Compound) Daunorubicin
Daunorubicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Neratinib
Everolimus (Compound) resembles Sirolimus (Compound) and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Neratinib
Everolimus (Compound) downregulates ERBB2 (Gene) and ERBB2 (Gene) is bound by Lapatinib (Compound) and Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Neratinib
Everolimus (Compound) resembles Sirolimus (Compound) and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib and Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Neratinib
Everolimus (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Lapatinib (Compound) and Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Neratinib
Everolimus (Compound) downregulates ERBB2 (Gene) and ERBB2 (Gene) is downregulated by Digoxin (Compound) and Digoxin may cause a moderate interaction that could exacerbate diseases when taken with Neratinib
Everolimus (Compound) resembles Sirolimus (Compound) and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Norethisterone and Norethisterone may cause a moderate interaction that could exacerbate diseases when taken with Neratinib
Everolimus (Compound) upregulates VAV3 (Gene) and VAV3 (Gene) is upregulated by Lapatinib (Compound) and Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Neratinib
Everolimus (Compound) resembles Sirolimus (Compound) and Sirolimus may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may cause a moderate interaction that could exacerbate diseases when taken with Neratinib
Everolimus (Compound) downregulates CCNB2 (Gene) and CCNB2 (Gene) is upregulated by Lapatinib (Compound) and Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Neratinib
Everolimus (Compound) upregulates BAMBI (Gene) and BAMBI (Gene) is downregulated by Daunorubicin (Compound) and Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Neratinib